Add Formweb to your mobile device
Search results for:
fosaprepitant
fosaprepitant
Brand names: Emend for Injection
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 150 mg | Emend IV restricted to use by medical oncologists for the prevention of acute and delayed emesis for moderately or highly emetogenic chemotherapy (see table above of Ematogenic Potential of Antineoplastic Agents) |
Last updated: Nov. 16, 2023
- Restricted: Emend IV restricted to use by medical oncologists for the prevention of acute and delayed emesis for moderately or highly emetogenic chemotherapy
Emetogenic Potential of Intravenous Antineoplastic Agents (NCCN Antiemesis Guidelines - Updated May 24, 2023)
High emetic risk (>90% frequency of emesis)
• AC combination defined as any chemotherapy regimen that contains an anthracycline and
cyclophosphamide
• Carboplatin AUC ≥4
• Carmustine >250 mg/m2
• Cisplatin
• Cyclophosphamide >1500 mg/m2
• Dacarbazine
• Doxorubicin ≥60 mg/m2
• Epirubicin >90 mg/m2
• Fam-trastuzumab deruxtecan-nxki
• Ifosfamide ≥2 g/m2
per dose
• Mechlorethamine
• Melphalan ≥140 mg/m2
• Sacituzumab govitecan-hziy
• Streptozocin
Moderate emetic risk (>30-90% frequency of emesis)
• Aldesleukin >12–15 million IU/m2
• Amifostine >300 mg/m2
• Bendamustine
• Busulfan
• Carboplatin AUC <4*
• Carmustine ≤250 mg/m2*
• Clofarabine
• Cyclophosphamide ≤1500 mg/m2*
• Cytarabine >200 mg/m2
• Dactinomycin*
• Daunorubicin*
• Dinutuximab
• Doxorubicin <60 mg/m2*
• Dual-drug liposomal encapsulation
of cytarabine and daunorubicin
• Epirubicin ≤90 mg/m2*
• Idarubicin*
• Ifosfamide <2 g/m2 per dose*
• Irinotecan*
• Irinotecan (liposomal)
• Lurbinectedin
• Melphalan <140 mg/m2
• Methotrexate ≥250 mg/m2*
• Naxitamab-gqgk
• Oxaliplatin*
• Romidepsin
• Temozolomide
• Trabectedin*
*These agents may be highly emetogenic in certain patients.